Home Newsfeeds Mizuho Initiates Coverage On BioXcel Therapeutics with Buy Rating, Announces Price Target of $19

Mizuho Initiates Coverage On BioXcel Therapeutics with Buy Rating, Announces Price Target of $19

Mizuho analyst Graig Suvannavejh initiates coverage on BioXcel Therapeutics (NASDAQ:BTAI) with a Buy rating and announces Price Target of $19.

byBenzinga Newsdesk

July 7, 2022

1 minute read

Mizuho analyst Graig Suvannavejh initiates coverage on BioXcel Therapeutics (NASDAQ:BTAI) with a Buy rating and announces Price Target of $19.

A Boxed Original iPhone Or S&P 500: Which Investment Triumphed In The Long Run?

By Shanthi Rexaline

June 7, 2:41 AM

Apple, Inc. (NASDAQ:AAPL) on Monday unveiled the Vision Pro mixed-reality headset, potentially its next big product after the…

AAPL

Analyst Ratings

What 8 Analyst Ratings Have To Say About Baker Hughes

By Benzinga Insights

July 13, 11:05 AM

Over the past 3 months, 8 analysts have published their opinion on Baker Hughes (NASDAQ:BKR) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a company's business to predict how a stock will trade over the upcoming year.

BKR

BlackBerry Q2 EPS $(0.05) Beats $(0.07) Estimate, Sales $168.00M Miss $177.25M Estimate

By Michael Horton

September 27, 5:05 PM

BlackBerry (NYSE:BB) reported quarterly losses of $(0.05) per share which beat the analyst consensus estimate of $(0.07) by 28.57 percent. This is a 16.67 percent increase over losses of $(0.06) per share from the same

Piper Sandler Maintains Overweight on Synchrony Finl, Lowers Price Target to $40

By Benzinga Newsdesk

September 26, 8:59 AM

Piper Sandler analyst Kevin Barker maintains Synchrony Finl (NYSE:SYF) with a Overweight and lowers the price target from $41 to $40.

SYF

Mizuho Initiates Coverage On BioXcel Therapeutics with Buy Rating, Announces Price Target of $19

Related Posts

A Boxed Original iPhone Or S&P 500: Which Investment Triumphed In The Long Run?

What 8 Analyst Ratings Have To Say About Baker Hughes

BlackBerry Q2 EPS $(0.05) Beats $(0.07) Estimate, Sales $168.00M Miss $177.25M Estimate

Piper Sandler Maintains Overweight on Synchrony Finl, Lowers Price Target to $40